Olaratumab: First Global Approval

Abstract CT145: A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS)

(2016) Victor Villalobos et al.   CANCER RESEARCH

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma

(2016) Christopher W. Ryan et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

(2014) Ian Judson et al.   LANCET ONCOLOGY

Targeting the PDGF signaling pathway in tumor treatment

(2013) Carl-Henrik Heldin   Cell Communication and Signaling

Stromal Platelet-Derived Growth Factor Receptor   (PDGFR ) Provides a Therapeutic Target Independent of Tumor Cell PDGFR  Expression in Lung Cancer Xenografts

(2012) D. E. Gerber et al.   MOLECULAR CANCER THERAPEUTICS

Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α

(2010) Gaurav D. Shah et al.   CANCER

Targeting the   Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis

(2010) M. R. Russell et al.   CLINICAL CANCER RESEARCH